PDGFRA and non-small cell lung carcinoma: Additionally, TP53, PIK3CA, KIT, FGFR1, PDGFRA, or NRAS were previously identified prevalent alterations in patients with NSCLC, and their impacts on target treatment or prognosis have received widespread attention.11, 12, 13